Goodness Growth Holdings Announces Third Quarter 2021 Financial Results

 
 

Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a physician-led, science-focused cannabis company and IP incubator, today reported financial results for its third quarter ended September 30, 2021 . All currency figures referenced in this press release reflect U.S. dollar amounts.

 
 

  Goodness Growth Holdings (CSE: GDNS; OTCQX: GDNSF) is the new parent company of Vireo Health and Green Goods. (PRNewsfoto/Goodness Growth Holdings) 

 
 

"Our third quarter results were negatively impacted by unseasonal weather in the State of Arizona , where monsoonal rains wiped out a substantial portion of our outdoor crop at Elephant Head Farm," said Chairman and Chief Executive Officer, Kyle Kingsley , M.D. "That loss of biomass severely impacted revenue and gross margin performance compared to our expectations, and results were also impacted sequentially by the non-recurrence of a high-margin wholesale order in New York that occurred in the second quarter. While we're disappointed with these results, crop yields in Arizona this fall may help our performance in the wholesale channel over the next two quarters."

 

Dr. Kingsley continued, "As we close out the fourth quarter and look to next year, we're looking forward to launching new edibles products and concentrates in the Maryland market, as well as the commencement of adult-use sales in New Mexico and beginning of flower sales in the Minnesota medical market this coming spring. Our operating teams also continue to make a lot of exciting progress in New York . We anticipate our new indoor cultivation and processing facility will be complete in the second quarter of 2022, and we've identified several promising incremental retail locations that will help us ensure a successful rollout under the adult-use program in 2023."

 
 
                                                                                                                      
 

   Summary of Key Financial Metrics   

 
 
 
 

  Three Months Ended  

 
 
 

  Nine Months Ended  

 
 

   US $ in millions   

 
 

  September 30,  

 
 
 

  September 30,  

 
 
 

  2021  

 
 
 

  2020  

 
 
 

  Variance  

 
 
 

  2021  

 
 
 

  2020  

 
 
 

  Variance  

 
 

  GAAP Revenue  

 
 

  $13.4  

 
 
 

  $12.5  

 
 
 

  7.2%  

 
 
 

  $40.8  

 
 
 

  $36.8  

 
 
 

  10.9%  

 
 

  Revenue (excl. former PA and OH subsidiaries)  

 
 

  $13.4  

 
 
 

  $10.5  

 
 
 

  27.6%  

 
 
 

  $40.7  

 
 
 

  $30.3  

 
 
 

  34.3%  

 
 

  GAAP Gross Profit  

 
 

  $5.1  

 
 
 

  $5.0  

 
 
 

  2.0%  

 
 
 

  $17.6  

 
 
 

  $11.8  

 
 
 

  49.2%  

 
 

   Gross Profit Margin   

 
 

   38.3%   

 
 
 

   39.8%   

 
 
 

   -150 bps   

 
 
 

   43.3%   

 
 
 

   32.1%   

 
 
 

   1,120 bps   

 
 

  SG&A Expenses  

 
 

  $8.1  

 
 
 

  $6.5  

 
 
 

  24.6%  

 
 
 

  $24.4  

 
 
 

  $19.7  

 
 
 

  23.9%  

 
 

   SG&A Expenses (% of Sales)   

 
 

   60.4%   

 
 
 

   52.0%   

 
 
 

   840 bps   

 
 
 

   59.8%   

 
 
 

   53.5%   

 
 
 

   630 bps   

 
 

  Adjusted EBITDA (non-GAAP)  

 
 

  ($1.9)  

 
 
 

  ($0.6)  

 
 
 

  NM  

 
 
 

  ($4.6)  

 
 
 

  ($5.5)  

 
 
 

  NM  

 
 

   Adjusted EBITDA Margin (non-GAAP)   

 
 

   (14.0%)   

 
 
 

   (4.8%)   

 
 
 

   -920 bps   

 
 
 

   (11.3%)   

 
 
 

   (14.9%)   

 
 
 

   360 bps   

 
 
 

 

 

 

 

  Third Quarter Financial Summary  

 

Total revenue was $13.4 million in the third quarter, an increase of 7.2 percent as compared to Q3 2020, including the Company's former subsidiaries in Pennsylvania and Ohio . Excluding contributions from Pennsylvania and Ohio , revenue increased 27.6 percent. Retail revenue excluding Pennsylvania increased 34.7 percent to $11.6 million in Q3 2021 and reflected growth in each of the Company's retail markets. Wholesale revenue, excluding Pennsylvania and Ohio declined by 5.0 percent to $1.8 million , driven by the loss of biomass due to atypical weather in the Arizona market, which resulted in a sales decline during the quarter.

 

Gross profit was $5.1 million , or 38.3 percent of revenue, as compared to gross profit of $5.0 million or 39.8 percent of revenue in Q3 last year. The relatively flat gross profit margin was driven by higher throughput and decreased fixed costs per unit across most markets, offset by the impact of lower sales and increased costs in Arizona .

 

Total operating expenses in the third quarter were $9.2 million , an increase of $2.0 million as compared to $7.2 million in the third quarter of 2020. The increase in total expenses was attributable to increased general and administrative expenses driven by operational buildouts in Arizona , Maryland , Minnesota , and New Mexico where the Company has opened new retail dispensaries or has completed cultivation and manufacturing expansion projects.

 

Total other expenses were $1.5 million during Q3 2021, compared to other income of $11.2 million in Q3 2020. The decrease was primarily attributable to a one-time gain of $16.9 million on the disposition of assets during the prior-year quarter, partially offset by a derivative gain and higher interest expenses in the current period.

 

EBITDA, as described in accompanying disclosures and footnotes, was a loss of $2.4 million during Q3 2021, compared to a gain of $11.1 million in Q3 2020. Adjusted EBITDA was a loss of $1.9 million in Q3 2021, as compared to a loss of $0.6 million in Q3 2020. Please refer to the Supplemental Information and Reconciliation of Non-GAAP Financial Measures at the end of this press release for additional information.

 

Net loss in Q3 2021 was $6.2 million , as compared net income of $3.0 million in Q3 2020. The variance compared to the prior year was driven by increased operating and other expenses, higher interest expenses, and the non-recurrence of the gain on disposition of assets in the prior-year quarter.

 

  Other Events  

 

On August 19, 2021 , the Company announced that it opened two new Green Goods® cannabis dispensaries in the state of New Mexico , located in Albuquerque and Las Cruces . These openings follow the Company's strategic investments in cultivation operations to prepare for New Mexico's adult-use program, which is expected to begin in April of 2022.

 

On September 1, 2021 , the Company announced that the United States Patent and Trademark Office issued a Notice of Allowance for its subsidiary company Resurgent Biosciences, Inc.'s patent application titled, "Cannabis Based Moist Snuff." This patent covers both the product delivery format and the process for creating a moist snuff from cannabis plants.

 

On September 28, 2021 , the Company announced that it had closed on a sale leaseback transaction with Innovative Industrial Properties, Inc. ("IIP") in the State of New York . IIP acquired approximately 92.3 acres of land adjacent to Goodness Growth's existing facility in Johnstown, NY . The purchase price for the land was approximately $1.2 million , excluding transaction costs, and IIP is expected to provide funds of approximately $66.0 million for the construction of a new 324,000 square foot cannabis cultivation, processing, and research and development facility.

 

On October 28, 2021 , the Company received regulatory approval of its acquisition of a dispensary license in Baltimore, Maryland . The previously-announced transaction is expected to close during the fourth quarter, and will bring the Company's total number of operating dispensaries in Maryland to two.

 

On October 30, 2021 , the Company announced that its wholly-owned subsidiary, Vireo Health of New York began selling whole flower cannabis products at its dispensaries and via its home delivery service in New York . The Company expects to have up to six cannabis flower strains available for patients in New York by the end of calendar year 2021.

 

On November 2, 2021 , the Company announced that it had entered into an agreement to sell its Arizona cannabis licenses, all remaining inventory and equipment at its Phoenix dispensary, the Phoenix dispensary property lease and all revenue producing dispensary contracts in an all-cash transaction valued at approximately $15.0 million . The Company will continue to operate the outdoor farm in Amado, AZ and sell wholesale cannabis and cannabis products, under a cultivation management services agreement with the new owner. The Company expects the transaction to close later this year, pending regulatory approval.

 

  Balance Sheet and Liquidity  

 

As of September 30, 2021 , the Company had 126,351,477 equity shares issued and outstanding on an as-converted basis, and 154,358,312 shares outstanding on an as-converted, fully diluted basis.

 

As of September 30, 2021 , total current assets were $44.8 million , including cash on hand of $11.8 million , which does not include $15.0 million in cash proceeds from the sale of the Company's Arizona licenses and Phoenix dispensary assets, which is expected to close during the fourth quarter. Total current liabilities were $15.2 million , with $1.1 million in debt due within 12 months.

 

  Outlook Commentary  

 

Dr. Kingsley commented, "Given our recent decision to focus solely on the wholesale market in Arizona , as well as uncertainty surrounding the start date of adult-use sales in the state of New York , we've revised our previous outlook ranges for financial performance in fiscal year 2022. We now expect fiscal year 2022 revenues to be in the range of $100 to $120 million , and adjusted EBITDA in the range of $20 to $30 million ."

 

  Conference Call and Webcast Information  

 

Goodness Growth management will host a conference call with research analysts today, Wednesday, November 10, 2021 at 8:30 a.m. ET ( 7:30 a.m. CT ) to discuss its financial results for its third quarter ended September 30, 2021 . Interested parties may register to attend the conference call via the following link: https://www.directeventreg.com/registration/event/1664907 .

 

Upon registration, each participant will be provided with call details and a registrant ID for Goodness Growth's conference ID number 1664907. A live audio webcast of this event will also be available in the Events & Presentations section of the Company's Investor Relations website and will be archived for one year.

 

  About Goodness Growth Holdings, Inc.  

 

Goodness Growth Holdings, Inc., is a physician-led, science-focused holding company whose mission is to bring the power of plants to the world. The Company's operations consist primarily of its multi-state cannabis company subsidiary, Vireo Health, and its science and intellectual property incubator, Resurgent Biosciences. The Company manufactures proprietary, branded cannabis products in environmentally friendly facilities and state-of-the-art cultivation sites, and distributes its products through its growing network of Green Goods® and other retail locations and third-party dispensaries. Its team of more than 500 employees are focused on the development of differentiated products, driving scientific innovation of plant-based medicines and developing meaningful intellectual property. Today, the Company is licensed to grow, process, and/or distribute cannabis in eight markets and operates 18 dispensaries across the United States . For more information about Goodness Growth Holdings, please visit www.goodnessgrowth.com .

 

  Additional Information  

 

Additional information relating to the Company's third quarter 2021 results will be available on EDGAR and SEDAR no later than November 12, 2021 . Goodness Growth refers to certain non-GAAP financial measures such as Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) and adjusted EBITDA (defined as earnings before interest, taxes, depreciation, and amortization, less certain non-cash equity compensation expense, one-time transactions, and other non-recurring non-cash items. These measures do not have any standardized meaning and may not be comparable to similar measures presented by other issuers. Please see the Supplemental Information and Reconciliation of Non-GAAP Financial Measures at the end of this news release for more detailed information regarding non-GAAP financial measures.

 
 
              
 

   Contact Information   

 
 
 
 
 

   Investor Inquiries:   

 
 

   Media Inquiries:   

 
 

  Sam Gibbons  

 
 

  Albe Zakes  

 
 

   Vice President, Investor Relations   

 
 

   Vice President, Corporate Communications   

 
 

   samgibbons@goodnessgrowth.com   

 
 

   albezakes@goodnessgrowth.com   

 
 

  (612) 314-8995  

 
 

  (267) 221-4800  

 
 
 

  Forward-Looking Statement Disclosure  

 

This press release contains "forward-looking information" within the meaning of applicable United States and Canadian securities legislation. To the extent any forward-looking information in this press release constitutes "financial outlooks" within the meaning of applicable United States or Canadian securities laws, such information is being provided as preliminary financial results and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks. Forward-looking information contained in this press release may be identified by the use of words such as "should," "looking forward," "may," "continues," "anticipate," "expect," "strategy,"  "outlook," "will," "believe,"  "range," "subject to," and "pending," or variations of such words and phrases. These statements should not be read as guarantees of future performance or results. Forward-looking information includes both known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company or its subsidiaries to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements or information contained in this press release. Financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to various risks as set out herein and in our Annual Report on Form 10-K filed with the Securities Exchange Commission. Our actual financial position and results of operations may differ materially from management's current expectations and, as a result, our revenue, adjusted EBITDA, and cash on hand may differ materially from the values provided in this press release. Forward-looking information is based upon a number of estimates and assumptions of management, believed but not certain to be reasonable, in light of management's experience and perception of trends, current conditions, and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.

 

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to, risks related to the timing of adult-use legislation in markets where the Company currently operates; current and future market conditions, including the market price of the subordinate voting shares of the Company; risks related to the COVID-19 pandemic; federal, state, local, and foreign government laws, rules, and regulations, including federal and state laws in the United States relating to cannabis operations in the United States and any changes to such laws; operational, regulatory and other risks; execution of business strategy; management of growth; difficulty to forecast; conflicts of interest; risks inherent in an agricultural business; liquidity and additional financing; and risk factors set out in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 , which is available on EDGAR with the U.S. Securities and Exchange Commission and filed with the Canadian securities regulators and available under the Company's profile on SEDAR at www.sedar.com .

 

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results, or otherwise, other than as required by applicable securities laws.

 

  Supplemental Information  

 

The financial information reported in this news release is based on audited financial statements for the fiscal year ended December 31, 2020 and unaudited condensed interim consolidated financial statements for the fiscal quarter ended September 30, 2021 . All financial information contained in this news release is qualified in its entirety with reference to such financial statements. To the extent that the financial information contained in this news release is inconsistent with the information contained in the Company's audited financial statements, the financial information contained in this news release shall be deemed to be modified or superseded by the Company's audited financial statements. The making of a modifying or superseding statement shall not be deemed an admission for any purposes that the modified or superseded statement, when made, constituted a misrepresentation for purposes of applicable securities laws.

 
 
                                                                                                                                                                                                                                                                 
 

   GOODNESS GROWTH HOLDINGS, INC.   

 
 

   CONSOLIDATED BALANCE SHEETS AS OF SEPTEMBER 30, 2021 AND DECEMBER 31, 2020   

 
 

   (Amounts Expressed in United States Dollars, Except for Share Amounts, Unaudited and Condensed)   

 
 
 

   September 30,   

 
 
 

   December 31,   

 
 
 

   2021   

 
 
 

   2020   

 
 

   Assets   

 
 
 
 
 
 
 

  Current assets:  

 
 
 
 
 
 
 

  Cash  

 
 

  $  

 
 

  11,779,295  

 
 
 

  $  

 
 

  25,513,180  

 
 

  Restricted cash  

 
 
 

  -  

 
 
 
 

  1,592,500  

 
 

  Accounts receivable, net of allowance for doubtful accounts of $189,467 and $132,490, respectively  

 
 
 

  975,205  

 
 
 
 

  696,994  

 
 

  Inventory  

 
 
 

  20,141,951  

 
 
 
 

  12,644,895  

 
 

  Prepayments and other current assets  

 
 
 

  3,145,490  

 
 
 
 

  1,552,278  

 
 

  Notes receivable  

 
 
 

  19,954  

 
 
 
 

  293,700  

 
 

  Deferred acquisition costs  

 
 
 

  -  

 
 
 
 

  28,136  

 
 

  Assets Held for Sale  

 
 
 

  8,692,419  

 
 
 
 

  4,596,445  

 
 

  Deferred financing costs  

 
 
 

  -  

 
 
 
 

  120,266  

 
 

  Total current assets  

 
 
 

  44,754,314  

 
 
 
 

  47,038,394  

 
 

  Property and equipment, net  

 
 
 

  99,954,310  

 
 
 
 

  30,566,259  

 
 

  Operating lease, right-of-use asset  

 
 
 

  8,417,965  

 
 
 
 

  8,163,844  

 
 

  Notes receivable, long-term  

 
 
 

  3,750,000  

 
 
 
 

  3,750,000  

 
 

  Intangible assets, net  

 
 
 

  5,421,895  

 
 
 
 

  8,409,419  

 
 

  Goodwill  

 
 
 

  183,836  

 
 
 
 

  3,132,491  

 
 

  Deposits  

 
 
 

  1,344,283  

 
 
 
 

  1,412,124  

 
 

  Deferred tax assets  

 
 
 

  337,000  

 
 
 
 

  157,000  

 
 

  Total assets  

 
 

  $  

 
 

  164,163,603  

 
 
 

  $  

 
 

  102,629,531  

 
 

   Liabilities   

 
 
 
 
 
 
 

  Current liabilities  

 
 
 
 
 
 
 

  Accounts Payable and Accrued liabilities  

 
 
 

  9,525,659  

 
 
 
 

  13,477,303  

 
 

  Right of use liability  

 
 
 

  1,403,465  

 
 
 
 

  857,294  

 
 

  Convertible notes, net of issuance costs  

 
 
 

  -  

 
 
 
 

  900,000  

 
 

  Long-Term debt, current portion  

 
 
 

  1,110,000  

 
 
 
 

  1,110,000  

 
 

  Liabilities held for sale  

 
 
 

  116,803  

 
 
 
 

  3,595,301  

 
 

  Warrant Liability  

 
 
 

  3,078,694  

 
 
 
 

  -  

 
 

  Total current liabilities  

 
 
 

  15,234,621  

 
 
 
 

  19,939,898  

 
 

  Right-of-use liability  

 
 
 

  78,606,734  

 
 
 
 

  20,343,063  

 
 

  Long-Term debt  

 
 
 

  19,411,212  

 
 
 
 

  -  

 
 

  Total liabilities  

 
 

  $  

 
 

  113,252,567  

 
 
 

  $  

 
 

  40,282,961  

 
 
 
 
 
 
 
 

   Stockholders' equity   

 
 
 
 
 
 
 

  Subordinate Voting Shares ($- par value, unlimited shares authorized; 79,538,377 shares issued and outstanding)  

 
 
 

  -  

 
 
 
 

  -  

 
 

  Multiple Voting Shares ($- par value, unlimited shares authorized; 402,720 shares issued and outstanding)  

 
 
 

  -  

 
 
 
 

  -  

 
 

  Super Voting Shares ($- par value; unlimited shares authorized; 65,411 shares issued and outstanding, respectively)  

 
 
 

  -  

 
 
 
 

  -  

 
 

  Additional Paid in Capital  

 
 
 

  171,354,487  

 
 
 
 

  164,079,614  

 
 

  Accumulated deficit  

 
 
 

  (120,443,451)  

 
 
 
 

  (101,733,044)  

 
 

  Total stockholders' equity  

 
 

  $  

 
 

  50,911,036  

 
 
 

  $  

 
 

  62,346,570  

 
 

   Total liabilities and stockholders' equity   

 
 

  $  

 
 

  164,163,603  

 
 
 

  $  

 
 

  102,629,531  

 
 
 

 

 
 
                                                                                                                                                                                                                                                                                                                                                                                        
 

   GOODNESS GROWTH HOLDINGS, INC.   

 
 

   CONSOLIDATED STATEMENTS OF OPERATIONS   

 
 

   THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020   

 
 

   (Amounts Expressed in United States Dollars, Except for Share Amounts, Unaudited and Condensed)   

 
 
 

   Three Months Ended September 30,   

 
 
 

   Nine Months Ended September 30,   

 
 
 

   2021   

 
 
 

   2020   

 
 
 

   2021   

 
 
 

   2020   

 
 

   Revenue   

 
 

  $  

 
 

  13,369,432  

 
 
 

  $  

 
 

  12,475,782  

 
 
 

  $  

 
 

  40,790,221  

 
 
 

  $  

 
 

  36,809,714  

 
 

   Cost of sales   

 
 
 
 
 
 
 
 
 
 
 
 
 

  Product costs  

 
 
 

  7,903,444  

 
 
 
 

  7,360,671  

 
 
 
 

  22,682,503  

 
 
 
 

  24,492,831  

 
 

  Inventory valuation adjustments  

 
 
 

  351,000  

 
 
 
 

  151,328  

 
 
 
 

  464,000  

 
 
 
 

  484,570  

 
 

  Gross profit  

 
 
 

  5,114,988  

 
 
 
 

  4,963,783  

 
 
 
 

  17,643,718  

 
 
 
 

  11,832,313  

 
 

   Operating expenses:   

 
 
 
 
 
 
 
 
 
 
 
 
 

  Selling, general and administrative  

 
 
 

  8,106,187  

 
 
 
 

  6,517,464  

 
 
 
 

  24,441,860  

 
 
 
 

  19,677,932  

 
 

  Stock-based compensation expenses  

 
 
 

  835,122  

 
 
 
 

  524,052  

 
 
 
 

  4,557,777  

 
 
 
 

  12,245,412  

 
 

  Depreciation  

 
 
 

  98,098  

 
 
 
 

  38,097  

 
 
 
 

  515,907  

 
 
 
 

  260,725  

 
 

  Amortization  

 
 
 

  206,442  

 
 
 
 

  153,356  

 
 
 
 

  619,327  

 
 
 
 

  461,737  

 
 

  Total operating expenses  

 
 
 

  9,245,849  

 
 
 
 

  7,232,969  

 
 
 
 

  30,134,871  

 
 
 
 

  32,645,806  

 
 
 
 
 
 
 
 
 
 
 
 
 
 

   Loss from operations   

 
 
 

  (4,130,861)  

 
 
 
 

  (2,269,186)  

 
 
 
 

  (12,491,153)  

 
 
 
 

  (20,813,493)  

 
 
 
 
 
 
 
 
 
 
 
 
 
 

   Other income (expense):   

 
 
 
 
 
 
 
 
 
 
 
 
 

  Loss on sale of property and equipment  

 
 
 

  -  

 
 
 
 

  -  

 
 
 
 

  -  

 
 
 
 

  (13,800)  

 
 

  Gain on disposal of assets held for sale  

 
 
 

  -  

 
 
 
 

  16,884,173  

 
 
 
 

  437,107  

 
 
 
 

  16,884,173  

 
 

  Loss on assets held for sale  

 
 
 

  -  

 
 
 
 

  (446,544)  

 
 
 
 

  -  

 
 
 
 

  (446,544)  

 
 

  Derivative gain (loss)  

 
 
 

  627,165  

 
 
 
 

  (4,066,335)  

 
 
 
 

  2,317,065  

 
 
 
 

  (5,032,537)  

 
 

  Interest expenses, net  

 
 
 

  (2,254,553)  

 
 
 
 

  (1,255,656)  

 
 
 
 

  (6,037,057)  

 
 
 
 

  (4,249,090)  

 
 

  Other income (expenses)  

 
 
 

  75,018  

 
 
 
 

  108,552  

 
 
 
 

  33,631  

 
 
 
 

  (205,061)  

 
 

  Other income (expenses), net  

 
 
 

  (1,552,370)  

 
 
 
 

  11,224,190  

 
 
 
 

  (3,249,254)  

 
 
 
 

  6,937,141  

 
 

  Loss before income taxes  

 
 
 

  (5,683,231)  

 
 
 
 

  8,955,004  

 
 
 
 

  (15,740,407)  

 
 
 
 

  (13,876,352)  

 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Current income tax expenses  

 
 
 

  (530,000)  

 
 
 
 

  (3,723,000)  

 
 
 
 

  (3,150,000)  

 
 
 
 

  (4,575,000)  

 
 

  Deferred income tax recoveries  

 
 
 

  (30,000)  

 
 
 
 

  (2,280,000)  

 
 
 
 

  180,000  

 
 
 
 

  (2,225,000)  

 
 

  Net loss and comprehensive loss  

 
 
 

  (6,243,231)  

 
 
 
 

  2,952,004  

 
 
 
 

  (18,710,407)  

 
 
 
 

  (20,676,352)  

 
 

  Net loss per share - basic and diluted  

 
 

  $  

 
 

  (0.05)  

 
 
 

  $  

 
 

  0.03  

 
 
 

  $  

 
 

  (0.15)  

 
 
 

  $  

 
 

  (0.22)  

 
 

  Weighted average shares used in computation of net loss per share - basic  

 
 
 

  126,363,104  

 
 
 
 

  98,871,038  

 
 
 
 

  122,704,872  

 
 
 
 

  95,433,233  

 
 

  Weighted average shares used in computation of net loss per share - diluted  

 
 
 

  126,363,104  

 
 
 
 

  112,517,113  

 
 
 
 

  122,704,872  

 
 
 
 

  95,433,233  

 
 
 

 

 
 
                                                                                                                                                                                                                                                                                                         
 

   GOODNESS GROWTH HOLDINGS, INC.   

 
 

   CONSOLIDATED STATEMENTS OF CASH FLOWS   

 
 

   NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020   

 
 
 

   Nine Months Ended September 30,   

 
 

   (Amounts Expressed in USD, Except for Share Amounts, Unaudited and Condensed)   

 
 

   2021   

 
 
 

   2020   

 
 

   CASH FLOWS FROM OPERATING ACTIVITIES   

 
 
 
 
 
 
 

  Net loss  

 
 

  $  

 
 

  (18,710,407)  

 
 
 

  $  

 
 

  (20,676,352)  

 
 

  Adjustments to reconcile net loss to net cash used in operating activities:  

 
 
 
 
 
 
 

  Inventory valuation adjustments  

 
 
 

  464,000  

 
 
 
 

  484,570  

 
 

  Depreciation  

 
 
 

  515,907  

 
 
 
 

  260,725  

 
 

  Depreciation capitalized into inventory  

 
 
 

  1,678,558  

 
 
 
 

  1,757,281  

 
 

  Non-cash operating lease expense  

 
 
 

  764,266  

 
 
 
 

  943,905  

 
 

  Amortization of intangible assets  

 
 
 

  619,327  

 
 
 
 

  461,737  

 
 

  Stock-based payments  

 
 
 

  4,557,777  

 
 
 
 

  12,245,412  

 
 

  Loss on assets held for sale  

 
 
 

  

 
 
 
 

  446,544  

 
 

  Interest Expense  

 
 
 

  1,764,711  

 
 
 
 

  

 
 

  Gain/loss  

 
 
 

  

 
 
 
 

  65,930  

 
 

  Deferred income tax  

 
 
 

  (180,000)  

 
 
 
 

  710,301  

 
 

  Gain on disposal of business  

 
 
 

  

 
 
 
 

  (16,884,173)  

 
 

  Accretion  

 
 
 

  310,704  

 
 
 
 

  573,573  

 
 

  Derivative (Gain) Loss  

 
 
 

  (2,317,065)  

 
 
 
 

  5,032,537  

 
 

  Gain on disposal of OMS  

 
 
 

  (437,107)  

 
 
 
 

  

 
 

  Change in operating assets and liabilities:  

 
 
 
 
 
 
 

  Accounts Receivable  

 
 
 

  18,384  

 
 
 
 

  (302)  

 
 

  Prepaid expenses  

 
 
 

  (1,573,909)  

 
 
 
 

  (239,174)  

 
 

  Inventory  

 
 
 

  (7,765,288)  

 
 
 
 

  (1,091,279)  

 
 

  Accounts payable and accrued liabilities  

 
 
 

  (2,555,634)  

 
 
 
 

  4,759,842  

 
 

  Held for sale assets and liabilities  

 
 
 

  8,575,615  

 
 
 
 

  153,146  

 
 

  Change in assets and liabilities held for sale  

 
 
 

  (8,450,772)  

 
 
 
 

  

 
 

  Net cash used in operating activities  

 
 

  $  

 
 

  (22,720,933)  

 
 
 

  $  

 
 

  (10,995,777)  

 
 
 
 
 
 
 
 

   CASH FLOWS FROM INVESTING ACTIVITIES:   

 
 
 
 
 
 
 

  PP&E Additions  

 
 

  $  

 
 

  (14,637,331)  

 
 
 

  $  

 
 

  (3,581,289)  

 
 

  Proceeds from sale of PAMS net of cash  

 
 
 

  

 
 
 
 

  16,637,489  

 
 

  Proceeds from sale of OMS net of cash  

 
 
 

  1,150,000  

 
 
 
 

  

 
 

  Deposits  

 
 
 

  67,841  

 
 
 
 

  282,943  

 
 

  Net cash provided by (used in) investing activities  

 
 

  $  

 
 

  (13,419,490)  

 
 
 

  $  

 
 

  13,339,143  

 
 
 
 
 
 
 
 

   CASH FLOWS FROM FINANCING ACTIVITIES   

 
 
 
 
 
 
 

  Proceeds from issuance of shares  

 
 

  $  

 
 

  

 
 
 

  $  

 
 

  7,613,490  

 
 

  Deferred financing costs  

 
 
 

  (865,769)  

 
 
 
 

  

 
 

  Proceeds from long-term debt  

 
 
 

  24,028,295  

 
 
 
 

  

 
 

  Convertible debt payment  

 
 
 

  (900,000)  

 
 
 
 

  

 
 

  Proceeds from option exercises  

 
 
 

  1,152,596  

 
 
 
 

  

 
 

  Debt interest payments  

 
 
 

  

 
 
 
 

  (65,962)  

 
 

  Lease payments  

 
 
 

  (1,008,584)  

 
 
 
 

  (1,250,799)  

 
 

  Net cash provided by financing activities  

 
 

  $  

 
 

  22,406,538  

 
 
 

  $  

 
 

  6,296,729  

 
 
 
 
 
 
 
 

  Net change in cash and restricted cash  

 
 

  $  

 
 

  (13,733,885)  

 
 
 

  $  

 
 

  8,640,095  

 
 
 
 
 
 
 
 

  Cash and restricted cash, beginning of period  

 
 

  $  

 
 

  25,513,180  

 
 
 

  $  

 
 

  9,234,173  

 
 
 
 
 
 
 
 

  Cash and restricted cash, end of period  

 
 

  $  

 
 

  11,779,295  

 
 
 

  $  

 
 

  17,874,268  

 
 
 

  Reconciliation of Non-GAAP Financial Measures  

 

EBITDA and Adjusted EBITDA are non-GAAP measures and do not have standardized definitions under GAAP. The following information provides reconciliations of the supplemental non-GAAP financial measures, presented herein to the most directly comparable financial measures calculated and presented in accordance with GAAP. The Company has provided the non-GAAP financial measures, which are not calculated or presented in accordance with GAAP, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with GAAP. These supplemental non- GAAP financial measures are presented because management has evaluated the financial results both including and excluding the adjusted items and believe that the supplemental non-GAAP financial measures presented provide additional perspective and insights when analyzing the core operating performance of the business. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented.

 
 
                                                                                                                                                                                                                  
 

   Reconciliation of Net Loss to EBITDA and Adjusted EBITDA   

 
 
 
 

   Three Months Ended   

 
 
 

   Nine Months Ended   

 
 
 

   September 30,   

 
 
 

   September 30,   

 
 
 

   2021   

 
 
 

   2020   

 
 
 

   2021   

 
 
 

   2020   

 
 

   Net income (loss)   

 
 

  $  

 
 

  (6,243,231)  

 
 
 

  $  

 
 

  2,952,004  

 
 
 

  $  

 
 

  (18,710,407)  

 
 
 

  $  

 
 

  (20,676,352)  

 
 

  Interest expense, net  

 
 
 

  2,254,553  

 
 
 
 

  1,255,656  

 
 
 
 

  6,037,057  

 
 
 
 

  4,249,090  

 
 

  Income taxes  

 
 
 

  560,000  

 
 
 
 

  6,003,000  

 
 
 
 

  2,970,000  

 
 
 
 

  6,800,000  

 
 

  Depreciation & Amortization  

 
 
 

  304,540  

 
 
 
 

  191,453  

 
 
 
 

  1,135,234  

 
 
 
 

  722,462  

 
 

  Depreciation included in cost of goods sold  

 
 
 

  691,662  

 
 
 
 

  699,432  

 
 
 
 

  1,678,558  

 
 
 
 

  1,757,281  

 
 
 
 
 
 
 
 
 
 
 
 
 
 

   EBITDA (non-GAAP)   

 
 

  $  

 
 

  (2,432,476)  

 
 
 

  $  

 
 

  11,101,545  

 
 
 

  $  

 
 

  (6,889,558)  

 
 
 

  $  

 
 

  (7,147,519)  

 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Derivative (Gain) Loss  

 
 
 

  (627,165)  

 
 
 
 

  4,066,335  

 
 
 
 

  (2,317,065)  

 
 
 
 

  5,032,537  

 
 

  Inventory adjustment  

 
 
 

  351,000  

 
 
 
 

  151,328  

 
 
 
 

  464,000  

 
 
 
 

  484,570  

 
 

  Share-based compensation  

 
 
 

  835,122  

 
 
 
 

  524,052  

 
 
 
 

  4,557,777  

 
 
 
 

  12,245,412  

 
 

  Severance Expense  

 
 
 

  -  

 
 
 
 

  -  

 
 
 
 

  -  

 
 
 
 

  339,997  

 
 

  Loss on assets held for sale  

 
 
 

  -  

 
 
 
 

  446,544  

 
 
 
 

  -  

 
 
 
 

  446,544  

 
 

  Gain on sale of discontinued operations  

 
 
 

  -  

 
 
 
 

  (16,884,173)  

 
 
 
 

  (437,107)  

 
 
 
 

  (16,884,173)  

 
 
 
 
 
 
 
 
 
 
 
 
 
 

   Adjusted EBITDA (non-GAAP)   

 
 

  $  

 
 

  (1,873,519)  

 
 
 

  $  

 
 

  (594,369)  

 
 
 

  $  

 
 

  (4,621,953)  

 
 
 

  $  

 
 

  (5,482,632)  

 
 
 

 

 

 

 
 
 

 Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/goodness-growth-holdings-announces-third-quarter-2021-financial-results-301420685.html  

 

SOURCE Goodness Growth Holdings, Inc.

 
 

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Closeup of lush green cannabis leaves.

Thailand Reverses Course on Cannabis, Moves to Recriminalize Amid Political Fallout

Thailand’s groundbreaking experiment with cannabis decriminalization is rapidly unraveling, with the government formally moving to reclassify the plant as a narcotic and ban recreational sales.

The decision has sent shockwaves through an industry once projected to be worth over US$1 billion.

The country’s Ministry of Public Health issued an order this week stating that cannabis only be sold with a medical prescription, effectively ending a short-lived era of liberal recreational access.

Keep reading...Show less
Cannabis leaf over map of Australia.

A State-by-State Guide to Cannabis in Australia

Australia federally legalised medicinal cannabis in 2016, and Australia's cannabis market has seen major growth since then.

Medical cannabis approvals were up by 120 percent in the first half of 2023 compared to the same period in 2022. Statista forecasts that Australian cannabis revenue will reach AU$3.73 billion in 2024 and grow at an annual rate of 3.22 percent, culminating in market volume worth AU$4.53 billion by 2029.

However, Australia’s cannabis industry is still young. Despite there being a strong case for a regulated market, which was outlined in a July 2024 report by the Penington Institute, recreational use is not legal and medical access remains limited and regulated.

Keep reading...Show less
Cannabis leaf on road marked with "2025," with sunlight in the background.

New Cannabis Consumption Trends, Regulatory Shifts Seen Driving Market in 2025

Understanding trends in the cannabis industry is paramount for investors eyeing a market with steady growth potential, but the landscape is complex as products and regulations continue to evolve.

Consumption habits are changing as edibles, vaping and THC beverages gain traction, especially among younger users, and cannabis companies are adapting their offerings to meet shifting demand.

Meanwhile, regulatory uncertainty, particularly surrounding the future of the US Farm Bill and state-level restrictions on hemp-derived cannabinoids, continues to challenge the market.

Despite these headwinds, production data and long-term growth forecasts suggest the cannabis industry remains on a promising — albeit turbulent — path. Read on for more on key trends to watch in 2025.

Consumption methods evolving post-legalization

Shifts in consumer behavior are reshaping markets across the board, and the cannabis industry is no exception.

While smoking remains the dominant method of cannabis consumption, a recent report from the Centers for Disease Control and Prevention highlights the growing popularity of edibles, vaping and dabbing.

The report notes that vaping and dabbing are particularly pronounced among younger adults.

A separate study published by the American Medical Association and funded in part by the Canadian Institutes of Health Research also points to how product preferences have changed among Canadian users since legalization in 2018.


The study indicates that while the use of flower, cannabis concentrates, oil, tinctures and topicals has decreased during that time, the use of vape cartridges, edibles and beverages has increased.

Edibles and beverages were legalized in Canada in late 2019, and Truss Beverage was one of the first players to introduce cannabis-infused drinks. Truss was a joint venture formed by Molson Coors Canada (TSX:TPX.A,TSX:TPX.B) and HEXO, a cannabis company that has since been acquired by Tilray Brands (TSX:TLRY,NASDAQ:TLRY).

In early 2020, Tilray launched a lineup of confectionery, wellness products and beverages through its subsidiary, High Park; Canopy Growth (TSX:WEED,NASDAQ:CGC) made a similar move. These companies gradually brought their products to the US as more states legalized cannabis for medical and/or recreational use.

Today, established cannabis brands typically offer edibles and beverages alongside their other products. Organigram Global (TSX:OGI,NASDAQ:OGI) is one of the newest US entrants, with its April acquisition of Collective Project providing immediate access to the US hemp-derived THC beverage market.

Growing awareness of health and wellness, potentially amplified by the pandemic-led adoption of health trackers, appears to be making an impact on the alcoholic beverage market.

A 2023 Gallup poll reveals a two decade decline in alcohol consumption, particularly among younger adults, suggesting a shift towards more health-conscious lifestyles within this demographic.

Craft beer production declined by 4 percent year-on-year in 2024, according to data collected by the Brewers Association. This marked the largest drop in the industry's history, excluding the pandemic. For small, independent craft breweries, 2024 marked the third consecutive year of declining production. A drop in the number of operating small breweries last year provides further evidence of this trend, with 501 closures in 2024 versus 434 openings.

Challenges in the alcohol market extend beyond the brewing industry, with the New York Times recently reporting the closure of a handful of nightclubs facing decreased alcohol sales alongside rising insurance and rent costs.

Meanwhile, cannabis lounges have been popping up across the US for the last several years. As of early 2025, several states had legalized or were in the process of implementing regulations for cannabis consumption lounges.

Hemp market growth despite regulatory uncertainty

The burgeoning hemp industry is another segment of the expanding cannabis market.

The legalization of industrial hemp — defined as cannabis with a THC concentration of 0.3 percent or less — through the 2018 Farm Bill led to initial investment and optimistic projections for CBD wellness products and various industrial applications. The sector’s rapid evolution also brought the rise of hemp-derived intoxicating cannabinoids, creating a market that presented both opportunities and complexities for participants.

However, after an initial boom, a lack of infrastructure and clearly defined regulations for CBD, as well as state-level variations and market oversupply, ultimately contributed to a quick retraction.

2024 was a pivotal year for the US hemp industry, as the hemp-related provisions of the 2018 Farm Bill — originally set to expire in September 2023, but extended to December 31, 2024 — created an urgent need to address critical issues like THC limits and the regulation of novel hemp-derived cannabinoids. A major point of contention was the proposed shift from defining hemp based on Delta-9 THC concentration (0.3 percent or less) to “total THC,” which includes THCA.

This change had the potential to significantly impact farmers and processors, as many hemp varieties that are compliant under the Delta-9 THC rule could exceed the 0.3 percent limit when THCA is included.

Various bills and amendments were proposed in 2024 as part of the Farm Bill discussions, each with different approaches to regulating hemp. Separate regulatory frameworks for industrial hemp and hemp grown for cannabinoids were suggested, and many states took their own action, leading to a patchwork of regulations and even outright bans.

Despite challenges, data from the US Department of Agriculture suggests signs of recovery.

The department's annual National Hemp Report from 2024 points to an 18 percent increase in industrial hemp production value between 2022 and 2023, with output growth seen in specific sectors like floral (18 percent), fiber (133 percent) and seed hemp (414 percent). The 2025 report from the Department of Agriculture indicates further expansion, with notable increases observed in both acreage (up 64 percent from 2023) and value (46 percent).

The 2024 Farm Bill ultimately did not pass, and right now the hemp industry is operating under a temporary extension of the 2018 Farm Bill under the American Relief Act of 2025, signed into law on December 21, 2024.

The 2018 Farm Bill is now set to expire on September 30, 2025.

While analysts for Markets and Markets project that the North American hemp industry will grow at a CAGR of 22.4 percent and ultimately reach a valuation of US$30.24 billion by 2029, the future of the industry will be heavily influenced by the outcome of the ongoing Farm Bill discussions.

US cannabis legalization remains stalled

Although there is clear demand for cannabis products, the now-defunct rescheduling process in the US is likely to continue casting a shadow of uncertainty over the industry's long-term trajectory.

Legal and procedural delays, including allegations of improper conduct and bias within the US Drug Enforcement Administration (DEA), led to hearing cancellations, and the new administration of US President Donald Trump has brought leadership changes to key agencies like the DEA and the Department of Justice.

Terry Cole, who Trump nominated to be DEA administrator on February 11, has a history of opposing cannabis legalization in the country. Similarly, Pam Bondi, Trump’s pick to lead the justice department, staunchly opposed a movement to legalize medical cannabis during her tenure as Florida’s attorney general.

While there have been bipartisan efforts in Congress to end federal cannabis prohibition and establish regulations for eventual legalization, the DEA’s actions and statements indicate a potential stall or reversal of progress.

In addition to that, new research is adding complexity to the debate.

A study published in the American Journal of Psychiatry this past March highlights an association between the use of high-potency cannabis strains and increased risks of psychosis, a factor that may not have been fully considered by the Department of Health and Human Services. As stronger cannabis strains become more widely available, a reassessment of their potential health risks may be required.

Investor takeaway

While the cannabis industry holds promise for growth and innovation, investors must remain acutely aware of the regulatory uncertainties and market volatility that will undoubtedly shape its trajectory in the years to come.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

Person touching a cannabis plant; Australia map in flag colours.

ASX Cannabis Stocks: 10 Biggest Companies

While Australia has yet to legalise all forms of cannabis, the country is a growing medical cannabis and hemp market, with many companies manufacturing, researching and exporting the plant-based product.

Medical cannabis was federally legalised in 2016, and the export of cannabis from Australia was legalised in 2018. As for recreational use, the only state to legalise recreational use and possession so far is the Australian Capital Territory, which did so in 2020, but it did not establish a regulated recreational cannabis market.

The country's medical cannabis market has been steadily expanding in size and scope. A Penington Institute report shows that Australians spent approximately AU$400 million on medicinal cannabis in the first half of 2024, 72 percent higher than the AU$234 million they spent over the entirety of 2022.

Keep reading...Show less
Cannabis leaves, gavel.

Cannabis Round-Up: Rescheduling Faces New Roadblocks, SAFER Banking Act Gets Another Look

February 2025 was characterized by an evolving legislative landscape and important financial updates from major players.

These developments underscore the complex and dynamic nature of the sector as it continues to navigate legal, financial, and regulatory challenges while experiencing ongoing growth and evolution.

Discussions around cannabis rescheduling, changes in federal agency leadership, state-level legalization efforts, and financial reports from key companies all contributed to a month of notable activity in the cannabis space.

Keep reading...Show less
Cannabis leaves, US flag.

Cannabis Round-Up: Banking Reform and Rescheduling De-Prioritized as Trump Takes Office

As a new year began, the cannabis industry saw a range of impactful events in January.

Legal obstacles continued to impede progress on a once-promising attempt to reschedule cannabis in the US, and President Donald Trump's leadership choices for key agencies are diminishing hopes it can be accomplished.

Meanwhile, cannabis banking reform won't be discussed at Wednesday's (February 5) meeting of the Standing Senate Committee on Banking, Commerce and the Economy, and Congress seems in no rush to address it.

Keep reading...Show less

Latest Press Releases

Related News

×